Precision Proteomics Inc (PPI) specializes in the development and application of innovative proteomics technologies to enable systematic and quantitative characterization of protein kinases and protein phosphorylation for biomedical precision medicine research and drug development.
Next-Generation
Phosphoproteomics For
Research And Precision
Medicine
Precision Proteomics
FEW WORDS ABOUT US
Precision Proteomics Inc. (PPI) is a biotechnology company commercializing a novel proteomics platform for basic, pre-clinical, and clinical research and for the development of next-generation precision medicine research. PPI’s patented technology – including the SH2 Supberbinder (SH2S)- enables cutting-edge proteomics to serve the needs of our customers and collaborators in research, development, and clinical utilization of therapeutics. PPI’s technology can systematically and quantitatively profile activations of key signal pathways and regulatory networks that drive pathogenesis or the development of resistance to therapy.
Besides providing valuable insights into the mechanism of action for targeted therapy and immunotherapy, PPI’s technology enables the identification of protein biomarkers for the precise utilization of therapeutics. The company is actively building research and development partnerships with academic institutions biopharmaceutical companies globally. Precision Proteomics Inc. has offices in London, Ottawa, and Toronto, Ontario, Canada.
Key Technology
PPI’s patented SH2 Superbinder (SH2S) binds phosphotyrosine like a magnet. When combined with advanced mass spectrometry, the SH2S platform enables ultra-sensitive phosphoproteomic analysis unattainable by conventional approaches.
Who Should Partner With
Precision Proteomics
Precision Proteomics Inc. (PPI) is a biotechnology company commercializing a novel proteomics platform for basic, pre-clinical, and clinical applications.
Contract Research Organizations (CROs)
If you conduct precision medicine research for pharmaceutical and biotechnology companies—we can help you deliver innovative research on proteomics and phosphoproteomics associated with biomarker discovery and drug development.
Pharmaceutical and Biotechnology Companies
If you work in pharmaceuticals or biotechnology, we can partner with you in drug target identification, mechanism of action study, biomarker identification, and development of companion diagnostics.
Investigators and Clinician Scientists
If your research requires proteomic analysis of biological or clinical samples, we will facilitate and add value to your research through our proprietary phosphoproteomics technology and tested-and-proven LC-MS/MS workflow.
Featured Products
One-stop solution for your needs in characterizing tyrosine phosphorylation. PPI offers a complete suit of affinity reagents, buffers, and easy-to-follow protocol for your needs in phosphotyrosine identification by mass spectrometry and other analytical platforms
SH2S-Magic Agarose beads (200 ul SH2S)
$499.00 USDSH2S Protein With GST Tag
$299.00 USD
(200 ug)SH2S Protein With (His)6 Tag
$299.00 USD
(200 ug)SH2S-Magno Magnetic Beads (200 ul)
$499.00 USD
Promotion: 20% off orders >$1,000
Our Services
Next-generation proteomics and prevision medicine enabled by ultra-high-resolution profiling of protein phosphorylation and pathogenic and immune signaling pathway activations
Ultra-deep and Quantitative
Phosphoproteomics by SH2S-MS
Discovery Tyr phosphoproteomics with unparalleled depth and breadth enabled by our SH2S AP-MS/MS pipeline, Complete phosphoproteomics (pY/pS/pT) by sequential SH2S and IMAC enrichment followed by MS/MS ,Quantitative proteomics and phosphoproteomics via isobaric labelling (eg., TMT)
Ultra High-Resolution Phosphoproteomics Empowered by the SH2S Technology
PPI’s core technology- the SH2 Superbinder, when combined with mass spectrometry, enables direct, systematic and quantitative profiling of protein kinase and immune signaling with exceptional sensitivity and at unprecedented resolution
Oncology and Immuno-Oncology –Pre-clinical and Clinical
Drug target and biomarker discovery, Drug screening and PD investigations, Subgroup analysis of trial readouts, Companion & molecular diagnostic development, Development strategy for combo therapies.
Our Resources
Representative publications on the discovery and applications of the SH2 Superbinder technology
Kaneko et al. Superbinder SH2 domains act as antagonists of cell signaling; Sci Signal. 2012 Sep 25;5(243):ra68. doi: 10.1126/scisignal.2003021
Bian et al. Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine super binder; Nat Chem Biol. 2016 Nov;12(11):959-966. DOI: 10.1038/nchembio.2178. Epub 2016 Sep 19.
Yao et al. One-Step SH2 Superbinder-Based Approach for Sensitive Analysis of Tyrosine Phosphoproteome; J Proteome Res. 2019 Apr 5;18(4):1870-1879. doi: 10.1021/acs.jproteome.9b00045
Chu et al. Photoaffinity-engineered protein scaffold for systematically exploring native phosphotyrosine signaling complexes in tumor samples. Proc Natl Acad Sci USA 2018, 115:E8863-E8872. DOI: 10.1073/pnas.1805633115
Custom Inquiry
We strive to add value to your research in proteomics
+1 (
